Latest Breaking News On - Plasma cell dyscrasias - Page 1 : vimarsana.com

Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting

Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSan diego convention centerDavid holmesErik holmlinEnze liuIndiana university school of medicineTherapies author links open overlay panelAmerican society of hematologyIndiana university medical centerCenter evaluation of addedBionano genomics incLineagen incCompany contactExchange commissionGilmartin group

AstraZeneca advances scientific leadership in hematology at ASH 2023

CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline New,.

United kingdomUnited statesSan diego convention centerSan diegoAnas younesGianluca pirozziDiego marinaLiud acalabrutinibHallb manchesterNational studyAlexion pharmaceuticals incPatients of the internationalAstrazeneca pharmaceuticalsLymphoma groupA analysis utilizing electronic health recordsHead of development

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSan diego convention centerSouth san franciscoSan diegoNicole keithSana biotechnology incAmerican society of hematology annual meetingAmerican societyHematology annual meetingCells that evade innateAdaptive immune rejectionLargeb cellLymphoma patients that areDiego convention centerSpecific in vivo genetic engineering

Bristol Myers Squibb s First Disclosures and New Data at ASH 2023 Highlight Company s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.

United statesSan diegoSikander ailawadhiFrancesco passamontiLisocabtagene maraleucelGuillaume cartronRavi vijMaroof hasanMark kaplanRachid bazHemophagocytic lymphohistiocytosisDanny jeyarajuSheida hayatiSusan balSamit hirawatFranck morschhauser

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPrnewswire cellcentricTim somervaillePaul richardsonAzim suraniLeif bergsagelDepartment of internal medicineUniversity of manchesterGurdon instituteHarvard medical schoolErnestn morial convention centerAmerican society of haematologyTakeda pharmaceuticalsUniversity of cambridgeClinical research